Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Juvaris BioTherapeutics

Request full access

Juvaris Biotherapeutics, Inc.

Burlingame, United StatesFounded 2001Biotech & Life Sciences

About Juvaris BioTherapeutics

Juvaris BioTherapeutics was a biotechnology company founded in 2001 by Jeff Fairman and Martin Cleary.

The company focused on developing adjuvanted vaccines and immunotherapeutics to treat infectious diseases and cancer in both humans and animals. The company is no longer in business.

Jeff Fairman, one of the co-founders, served as the Vice President of Research. His entrepreneurial background and expertise in immunology were instrumental in shaping the company's direction. After Juvaris, Fairman went on to found Vaxcyte, Inc. in 2013, where he continues to serve as Vice President of Research, demonstrating his continued commitment to vaccine development.

Juvaris BioTherapeutics developed a platform technology designed to induce strong and broad-based immune responses. This technology was the cornerstone of their product development efforts, which included a pipeline of immunotherapeutics and adjuvanted vaccines. The company's business model was centered on leveraging this platform to create a portfolio of products for various therapeutic areas. The company operated in the biotechnology and pharmaceutical markets, targeting both human and animal health sectors.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Oct 2010 $750K — Undisclosed —
SERIES BOther financing Apr 2010 $13M $50M Kleiner Perkins · SV Health Investors —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Juvaris BioTherapeutics website traffic

Latest recorded traffic for Juvaris BioTherapeutics is 0 monthly website visits. Juvaris BioTherapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Juvaris BioTherapeutics in the Burlingame ecosystem

Live from Dealroom

The Juvaris BioTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Burlingame HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Juvaris BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Juvaris BioTherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.